Treace Announces Participation in the UBS Global Healthcare Conference
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, announced its participation in the upcoming UBS Global Healthcare Conference. CEO John T. Treace and CFO Mark L. Hair will engage in a fireside chat on November 12, 2024, at 11:45 am ET. The event will be accessible via live webcast and replay on the company's investor relations website.
Treace Medical Concepts (NasdaqGS: TMCI), un’azienda tecnologica medica specializzata nei trattamenti chirurgici per le borsiti e le deformità del piede medio attraverso le sue procedure Lapiplasty® e Adductoplasty®, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute UBS. Il CEO John T. Treace e il CFO Mark L. Hair interverranno in una chiacchierata informale il 12 novembre 2024, alle 11:45 ora orientale. L'evento sarà accessibile tramite diretta web e registrazione sul sito delle relazioni con gli investitori dell'azienda.
Treace Medical Concepts (NasdaqGS: TMCI), una empresa de tecnología médica especializada en tratamientos quirúrgicos para juanetes y deformidades del mediopié a través de sus procedimientos Lapiplasty® y Adductoplasty®, anunció su participación en la próxima Conferencia Global de Salud de UBS. El CEO John T. Treace y el CFO Mark L. Hair participarán en una charla informal el 12 de noviembre de 2024, a las 11:45 a.m. ET. El evento será accesible a través de una transmisión en vivo y una repetición en el sitio web de relaciones con inversionistas de la empresa.
Treace Medical Concepts (NasdaqGS: TMCI)는 Lapiplasty® 및 Adductoplasty® 절차를 통해 무지외반증 및 중족골 기형에 대한 외과 치료를 전문으로 하는 의료 기술 회사이며, UBS 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO John T. Treace와 CFO Mark L. Hair는 2024년 11월 12일 오전 11시 45분 ET에 파이어사이드 챗에 참여할 예정입니다. 이 이벤트는 회사의 투자자 관계 웹사이트를 통해 라이브 웹캐스트와 재방송으로 접속할 수 있습니다.
Treace Medical Concepts (NasdaqGS: TMCI), une entreprise de technologie médicale spécialisée dans les traitements chirurgicaux pour les oignons et les déformations du médio-pied grâce à ses procédures Lapiplasty® et Adductoplasty®, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé UBS. Le PDG John T. Treace et le directeur financier Mark L. Hair participeront à une discussion informelle le 12 novembre 2024 à 11h45 ET. L'événement sera accessible via un webinaire en direct et une rediffusion sur le site des relations avec les investisseurs de l'entreprise.
Treace Medical Concepts (NasdaqGS: TMCI), ein Medizintechnikunternehmen, das sich auf chirurgische Behandlungen von Hallux Valgus und Mittel Fußdeformitäten durch die Verfahren Lapiplasty® und Adductoplasty® spezialisiert hat, gab seine Teilnahme an der bevorstehenden UBS Global Healthcare Conference bekannt. CEO John T. Treace und CFO Mark L. Hair werden am 12. November 2024 um 11:45 Uhr ET in einem informellen Gespräch teilnehmen. Die Veranstaltung ist über einen Live-Webcast und eine Wiederholung auf der Website der Investor Relations des Unternehmens zugänglich.
- None.
- None.
PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 11:45 am ET.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When is Treace Medical Concepts (TMCI) presenting at the UBS Global Healthcare Conference?
How can investors watch Treace Medical Concepts' (TMCI) UBS Conference presentation?
Who will represent Treace Medical Concepts (TMCI) at the UBS Healthcare Conference?
